Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
SHC Catalyst Timeline
Dated clinical, regulatory and corporate events for Sotera Health Company
Past FDA Catalysts and PDUFA Decisions
How SHC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Sotera Health Company is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every SHC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Petras Michael B. Jr.Director, Officer (Executive Chairman) | Sell | -294,515 397,912 held | $18.50 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SHC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 1.5 % (7.1 %) | 69.71 M | 2.96 M | 24.47% ( 582.00 K) |
Ownership Trends
SHC Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How SHC ranks across every disease it competes in
SHC News
Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
Sotera Health reported a 4.4% increase in Q3 2026 net revenues, totaling $58 million in net income. Adjusted EBITDA rose by 3.9%, with a 12% increase in Adjusted EPS to $0.29. The company reaffirmed its full-year growth outlook, despite a revenue decline in its Nordion segment due to Co-60 harvest timing.
Read more →Sotera Health Announces Third-Quarter 2026 Earnings Release Date
Sotera Health Company plans to release its third-quarter financial results on November 3, 2026. The results will be shared before market opening, followed by a conference call at 9:00 a.m. ET. Investors can access a live webcast and updates on the company's website.
Read more →Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
Sotera Health Company reported robust financial results for Q2 and the first half of 2026, with net revenues up 9.2% and net income significantly increasing to $54 million. The company also raised its full-year outlook for both revenue and adjusted EBITDA growth, reflecting strong performance across its business segments. CEO Alton Shader expressed confidence in the company's growth strategy and customer relationships.
Read more →Sotera Health Announces Second-Quarter 2026 Earnings Release Date
Sotera Health Company has announced the release date for its second-quarter 2026 earnings, set for August 6, 2026. The financial results will be available before market opening, followed by a conference call at 9:00 a.m. EDT. Investors can access a live webcast of the call and find updates on the company's website.
Read more →Sotera Health Announces Secondary Offering of Common Stock
Sotera Health Company has announced a secondary offering of 31,838,253 shares of common stock, which are being sold by affiliates of Warburg Pincus LLC and GTCR LLC. The company itself will not be selling any shares or receiving any proceeds from this offering, as it will only cover associated expenses. Goldman Sachs & Co. LLC is serving as the underwriter for this transaction. The announcement emphasizes potential risks related to the offering that could affect shareholder value.
Read more →Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
Sotera Health reported a strong financial performance for Q1 2026, with net revenues increasing by 10% year-over-year. The company achieved a net income of $27 million, a significant improvement from a loss in Q1 2025. Adjusted EBITDA also saw a 10.5% increase, and the company reaffirmed its full-year growth outlook. The positive results were driven by strong performance in its Sterigenics and Nordion segments.
Read more →Sotera Health Announces Leadership Transition
Sotera Health announced a leadership transition with Alton Shader set to become CEO on May 26, 2026, succeeding Michael B. Petras, Jr. Petras will assume the role of Executive Chairman and continue to guide the company. Shader, with extensive experience in the medical industry, aims to build on Sotera's success in providing critical healthcare services.
Read more →Sotera Health Announces First-Quarter 2026 Earnings Release Date
Sotera Health Company has announced that it will release its financial results for the first quarter of 2026 before the market opens on May 5, 2026. Following the announcement, management will conduct a conference call to discuss the operating and financial results at 9:00 a.m. EDT. The company continues to emphasize its commitment to providing essential sterilization solutions and advisory services to the healthcare sector.
Read more →Sotera Health Appoints Kenneth D. Krause to the Board of Directors
Sotera Health Company has appointed Kenneth D. Krause as an independent director to its Board of Directors, effective March 16, 2026. Krause brings over ten years of experience as a public company CFO and a strong background in strategy and financial governance. He will serve on the Audit and Litigation Committees. Additionally, Dean S. Mihas has resigned from the Board due to a reduction in the number of directors designated by certain stockholders, ending his service since October 2020.
Read more →Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook
Sotera Health Company reported a 4.6% increase in fourth-quarter 2025 net revenues, marking its 20th consecutive year of revenue growth. The company achieved a net income of $35 million for the quarter and $78 million for the full year, driven by strong demand for its sterilization and lab testing services. Looking ahead, Sotera Health is optimistic about its financial outlook for 2026.
Read more →Sotera Health Announces Fourth-Quarter and Full-Year 2025 Earnings Release Date
Sotera Health Company has announced the release date for its fourth-quarter and full-year 2025 earnings. The financial results will be available before the market opens on February 24, 2026, followed by a conference call at 9:00 a.m. ET to discuss the results. The event will be accessible via a live webcast.
Read more →Sotera Health Appoints Richard Kyle to the Board of Directors
Sotera Health has appointed Richard G. Kyle as an independent director on its Board of Directors. Kyle, who previously served as CEO of The Timken Company, brings extensive experience in global operations and financial management. He will also participate in the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee.
Read more →Sotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company presented a positive outlook at the 44th Annual J.P. Morgan Healthcare Conference, projecting 2025 revenue to exceed $1.16 billion, marking over 20 years of growth. CEO Michael B. Petras, Jr. emphasized the company's robust financial position and commitment to customer service. However, the company faces several risks, including potential supply chain disruptions and ongoing legal challenges that could affect financial stability. The full-year results and future outlook are set to be discussed on February 24, 2026.
Read more →Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
Sotera Health Company announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. The company's management will present at 1:30 p.m. ET and will also hold investor meetings. A live webcast of the presentation will be available on their website, with a replay accessible within 48 hours.
Read more →Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results
Sotera Health Company reported robust financial results for Q3 and year-to-date 2025, with net revenues rising by 9.1% to $311 million and net income increasing significantly. The company achieved double-digit growth in Adjusted EBITDA and reaffirmed its revenue outlook for the year while raising its Adjusted EBITDA forecast. However, pending settlements related to ethylene oxide claims pose potential risks.
Read more →Sotera Health Announces Third-Quarter 2025 Earnings Release Date
Sotera Health Company has announced the date for its third-quarter 2025 earnings release, scheduled for November 4, 2025. The company will provide financial results for the quarter ended September 30, 2025, before the market opens. Following the release, a conference call will be held to discuss the results and highlights.
Read more →